Loss of SPARC protects hematopoietic stem cells from chemotherapy toxicity by accelerating their return to quiescence

Blood

Volumn 123, Issue 26, 2014, Pages 4054-4063

  Ehninger, Armin ^a,b   Boch, Tobias ^a,b   Medyouf, Hind ^a,b   M̈udder, Katja ^a,b   Orend, Gertraud ^c   Trumpp, Andreas ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Hi STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine GmbH   (Germany)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; OSTEONECTIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CELL PROTECTION; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; LIVER; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN DEPLETION; QUIESCENCE; STEM CELL NICHE; SURVIVAL; TUMOR RESISTANCE;

ALLOGRAFTS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELLULAR MICROENVIRONMENT; FLUOROURACIL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; MICE; MICE, KNOCKOUT; OSTEONECTIN; TRANSPLANTATION CHIMERA;

EID: 84903640882     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-533711     Document Type: Article

References (49)

1. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1994;1(8):661-673. (Pubitemid 124000730)
2. Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to selfrenewal during homeostasis and repair. Cell. 2008;135(6):1118-1129.
3. Foudi A, Hochedlinger K, Van Buren D, et al. Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat Biotechnol. 2009;27(1):84-90.
4. Venezia TA, Merchant AA, Ramos CA, et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2004;2(10):e301.
5. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-908.
6. Harrison DE, Lerner CP. Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood. 1991;78(5):1237-1240.
7. Randall TD, Weissman IL. Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood. 1997;89(10):3596-3606. (Pubitemid 27227082)
8. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature. 2010;465(7299): 793-797.
9. Rivera LB, Bradshaw AD, Brekken RA. The regulatory function of SPARC in vascular biology. Cell Mol Life Sci. 2011;68(19):3165-3173.
10. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001;19(8):816-827.
11. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21(9):1931-1936. (Pubitemid 47299966)
12. Luo Z, Luo P, Yu Y, Zhao Q, Zhao X, Cheng L. SPARC promotes the development of erythroid progenitors. Exp Hematol. 2012;40(10):828-836.
13. Siva K, Jaako P, Miharada K, et al. SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q-myelodysplastic syndrome. Leukemia. 2012; 26(11):2416-2419.
14. Tripodo C, Sangaletti S, Guarnotta C, et al. Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood. 2012;120(17): 3541-3554.
15. DiMartino JF, Lacayo NJ, Varadi M, et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 2006;20(3):426-432. (Pubitemid 43291739)
16. Delany AM, Kalajzic I, Bradshaw AD, Sage EH, Canalis E. Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology. 2003;144(6): 2588-2596. (Pubitemid 36637090)
17. Bradshaw AD, Reed MJ, Sage EH. SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem. 2002;50(1):1-10. (Pubitemid 34074617)
18. Rodríguez CI, Buchholz F, Galloway J, et al. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet. 2000;25(2): 139-140. (Pubitemid 30394979)
19. Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995; 269(5229):1427-1429.
20. Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, Flavell RA. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp Med. 2001; 193(6):741-754.
21. Hayashi S, Lewis P, Pevny L, McMahon AP. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech Dev. 2002;119(Suppl 1):S97-S101. (Pubitemid 39658693)
22. Tesio M, Oser GM, Baccelli I, et al. Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization. J Exp Med. 2013;210(11): 2337-2349.
23. Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell. 1996;86(6):897-906. (Pubitemid 26336794)
24. Müller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E. Development of hematopoietic stem cell activity in the mouse embryo. Immunity. 1994;1(4):291-301.
25. Mikkola HK, Orkin SH. The journey of developing hematopoietic stem cells. Development. 2006; 133(19):3733-3744. (Pubitemid 44650952)
26. Christensen JL, Wright DE, Wagers AJ, Weissman IL. Circulation and chemotaxis of fetal hematopoietic stem cells. PLoS Biol. 2004; 2(3):E75.
27. Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med. 2011;208(3): 421-428.
28. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012; 481(7382):457-462.
29. Norose K, Clark JI, Syed NA, et al. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci. 1998;39(13): 2674-2680. (Pubitemid 28558226)
30. Ijiri K, Potten CS. Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer. 1987;55(2):113-123. (Pubitemid 17021671)
31. Kennedy BJ. 5-fluorouracil toxicity: old or new? Cancer. 1999;86(7):1099-1100. (Pubitemid 29446989)
32. Bowie MB, Kent DG, Dykstra B, et al. Identification of a new intrinsically timed developmental checkpoint that reprograms key hematopoietic stem cell properties. Proc Natl Acad Sci USA. 2007;104(14):5878-5882. (Pubitemid 47175627)
33. Bowie MB, McKnight KD, Kent DG, McCaffrey L, Hoodless PA, Eaves CJ. Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect. J Clin Invest. 2006;116(10):2808-2816. (Pubitemid 44511644)
34. Lin KK, Rossi L, Boles NC, Hall BE, George TC, Goodell MA. CD81 is essential for the re-entry of hematopoietic stem cells to quiescence following stress-induced proliferation via deactivation of the Akt pathway. PLoS Biol. 2011;9(9):e1001148.
35. Yamazaki S, Ema H, Karlsson G, et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell. 2011;147(5):1146-1158.
36. Yamazaki S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H. TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood. 2009;113(6):1250-1256.
37. Rivera LB, Brekken RA. SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-b1 activity. J Cell Biol. 2011; 193(7):1305-1319.
38. Park D, Spencer JA, Koh BI, et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell. 2012;10(3):259-272.
39. Arai F, Hirao A, Ohmura M, et al. Tie2/ angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149-161. (Pubitemid 38962572)
40. Thorén LA, Liuba K, Bryder D, et al. Kit regulates maintenance of quiescent hematopoietic stem cells. J Immunol. 2008;180(4):2045-2053.
41. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007; 1(6):685-697. (Pubitemid 350215333)
42. Brenet F, Kermani P, Spektor R, Rafii S, Scandura JM. TGFb restores hematopoietic homeostasis after myelosuppressive chemotherapy. J Exp Med. 2013;210(3):623-639.
43. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem. 1991;266(23):14831-14834. (Pubitemid 21907577)
44. Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008;11(6):231-246.
45. Pellagatti A, Jädersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA. 2007;104(27): 11406-11411. (Pubitemid 47175153)
46. Fenouille N, Puissant A, Dufies M, et al. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res. 2010;70(23):9659-9670.
47. Alachkar H, Santhanam R, Maharry K, et al. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest. 2014;124(4):1512-1524.
48. Meyer PN, Fu K, Greiner T, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol. 2011;135(1): 54-61.
49. Uehara H, Luo L, Simonis J, Singh N, Taylor EW, Ambati BK. Anti-SPARC oligopeptide inhibits laser-induced CNV in mice. Vision Res. 2010; 50(7):674-679.